Dx & Vx Co Valuation Multiples
Dx & Vx Co is valued at $139M as of November 2026, a 5.3x revenue multiple. In the last fiscal year, Dx & Vx Co revenue was $22M and Dx & Vx Co EBITDA was ($20M).
Dx & Vx Co Overview
About Dx & Vx Co
Dx & Vx Co Ltd is a bio-healthcare company operating in the following business segments: Medical Diagnosis, Healthcare, and New Drug Development. The majority of its revenue is generated from the Healthcare segment, which utilizes diagnostic technology to provide integrated biohealthcare solutions for microbiome-based diseases, and offers health functional foods for prevention, over-the-counter and prescription drugs for treatment, and lifestyle and hygiene products for management. The Medical Diagnosis segment provides preimplantation, prenatal, neonatal, and adult genomic testing and microbiome analysis services, and the New Drug Development business is involved in the research and development of COVID vaccines and treatment, microbiome respiratory vaccine, and mRNA anticancer vaccine.
Founded
2001
HQ
Employees
121
Website
Financials (Last FY)
EV
$114M
Valuation Multiples
Start free trial
Dx & Vx Co Financials
Dx & Vx Co reported last fiscal year revenue of $22M and negative EBITDA of ($20M).
In the same fiscal year, Dx & Vx Co generated $2M in gross profit, ($20M) in EBITDA losses, and had net loss of ($21M).
Dx & Vx Co P&L
In the most recent fiscal year, Dx & Vx Co reported revenue of $22M and EBITDA of ($20M).
Dx & Vx Co is unprofitable as of last fiscal year, with gross margin of 11%, EBITDA margin of (94%), and net margin of (99%).
Financial data powered by Morningstar, Inc.
Dx & Vx Co Stock Performance
Dx & Vx Co has current market cap of $139M, and enterprise value of $114M.
Market Cap Evolution
Dx & Vx Co's stock price is $1.42.
Dx & Vx Co share price increased by 4.0% in the last 30 days.
Dx & Vx Co has an EPS (earnings per share) of $-0.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $114M | $139M | -0.1% | 4.0% | -23.1% | - | $-0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDx & Vx Co Valuation Multiples
Dx & Vx Co trades at 5.3x EV/Revenue multiple, and (5.6x) EV/EBITDA.
Dx & Vx Co Financial Valuation Multiples
As of November 8, 2026, Dx & Vx Co has market cap of $139M and EV of $114M.
Dx & Vx Co has a P/E ratio of (6.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dx & Vx Co Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dx & Vx Co Margins & Growth Rates
In the most recent fiscal year, Dx & Vx Co reported gross margin of 11%, EBITDA margin of (94%), and net margin of (99%).
Dx & Vx Co Margins
Dx & Vx Co Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Dx & Vx Co Operational KPIs
Dx & Vx Co's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Dx & Vx Co Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Dx & Vx Co competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Dx & Vx Co
Dx & Vx Co has acquired 1 company to date.
Last acquisition by Dx & Vx Co was on April 12th 2023. Dx & Vx Co acquired Avixgen for $17M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Dx & Vx Co
| Description | Avixgen is a biopharmaceutical firm advancing protein-based therapeutics for inflammatory and autoimmune diseases through proprietary drug development platforms. |
| HQ Country | |
| HQ City | Seoul |
| Deal Date | 12 Apr 2023 |
| Valuation | $17M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Dx & Vx Co acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dx & Vx Co
| When was Dx & Vx Co founded? | Dx & Vx Co was founded in 2001. |
| Where is Dx & Vx Co headquartered? | Dx & Vx Co is headquartered in South Korea. |
| How many employees does Dx & Vx Co have? | As of today, Dx & Vx Co has over 121 employees. |
| Is Dx & Vx Co publicly listed? | Yes, Dx & Vx Co is a public company listed on Korea Exchange. |
| What is the stock symbol of Dx & Vx Co? | Dx & Vx Co trades under 180400 ticker. |
| When did Dx & Vx Co go public? | Dx & Vx Co went public in 2015. |
| Who are competitors of Dx & Vx Co? | Dx & Vx Co main competitors include |
| What is the current market cap of Dx & Vx Co? | Dx & Vx Co's current market cap is $139M. |
| What is the current revenue of Dx & Vx Co? | Dx & Vx Co's last fiscal year revenue is $22M. |
| What is the current EV/Revenue multiple of Dx & Vx Co? | Current revenue multiple of Dx & Vx Co is 5.3x. |
| Is Dx & Vx Co profitable? | No, Dx & Vx Co is not profitable. |
| How many companies Dx & Vx Co has acquired to date? | As of November 2026, Dx & Vx Co has acquired 1 company. |
| What was the largest acquisition by Dx & Vx Co? | $17M acquisition of Avixgen on 12th April 2023 was the largest M&A Dx & Vx Co has done to date. |
| What companies Dx & Vx Co acquired? | Dx & Vx Co acquired Avixgen. |
| In how many companies Dx & Vx Co has invested to date? | Dx & Vx Co hasn't invested in any companies yet (or none have been disclosed publicly). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.